Exact Mass: 327.1617

Exact Mass Matches: 327.1617

Found 92 metabolites which its exact mass value is equals to given mass value 327.1617, within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error 0.001 dalton.

N1-(2-Methoxy-4-methylbenzyl)-n2-(2-(pyridin-2-yl) ethyl)oxalamide

N-[(2-methoxy-4-methylphenyl)methyl]-N-[2-(pyridin-2-yl)ethyl]ethanediamide

C18H21N3O3 (327.1583)


N1-(2-Methoxy-4-methylbenzyl)-n2-(2-(pyridin-2-yl) ethyl)oxalamide is used as a food additive [EAFUS] ("EAFUS: Everything Added to Food in the United States. [http://www.eafus.com/]")

   

Cinereain

(4E)-4-(2-methylpropylidene)-7-(propan-2-yl)-15-oxa-2,5,8-triazatricyclo[8.5.0.0³,⁸]pentadeca-1(10),2,11,13-tetraene-6,9-dione

C18H21N3O3 (327.1583)


Cinereain is found in cereals and cereal products. Cinereain is isolated from Botrytis cinerea on sunflower seed. Isolated from Botrytis cinerea on sunflower seed. Cinereain is found in cereals and cereal products.

   

3,4-dimethylideneheptanedioylcarnitine

3-[(6-carboxy-3,4-dimethylidenehexanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H25NO6 (327.1682)


3,4-dimethylideneheptanedioylcarnitine is an acylcarnitine. More specifically, it is an 3,4-dimethylideneheptanedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3,4-dimethylideneheptanedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3,4-dimethylideneheptanedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Nona-4,7-dienedioylcarnitine

3-[(8-carboxyocta-4,7-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H25NO6 (327.1682)


nona-4,7-dienedioylcarnitine is an acylcarnitine. More specifically, it is an nona-4,7-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. nona-4,7-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine nona-4,7-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Nona-3,7-dienedioylcarnitine

3-[(8-carboxyocta-3,7-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H25NO6 (327.1682)


nona-3,7-dienedioylcarnitine is an acylcarnitine. More specifically, it is an nona-3,7-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. nona-3,7-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine nona-3,7-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Nona-4,6-dienedioylcarnitine

3-[(8-Carboxyocta-4,6-dienoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C16H25NO6 (327.1682)


nona-4,6-dienedioylcarnitine is an acylcarnitine. More specifically, it is an nona-4,6-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. nona-4,6-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine nona-4,6-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

(2E,7E)-Nona-2,7-dienedioylcarnitine

3-[(8-carboxyocta-2,7-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H25NO6 (327.1682)


(2E,7E)-nona-2,7-dienedioylcarnitine is an acylcarnitine. More specifically, it is an (2E,7E)-nona-2,7-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. (2E,7E)-nona-2,7-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine (2E,7E)-nona-2,7-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Nona-3,6-dienedioylcarnitine

3-[(8-carboxyocta-3,6-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H25NO6 (327.1682)


Nona-3,6-dienedioylcarnitine is an acylcarnitine. More specifically, it is an nona-3,6-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. nona-3,6-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine nona-3,6-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

Nona-5,7-dienedioylcarnitine

3-[(8-carboxyocta-5,7-dienoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H25NO6 (327.1682)


Nona-5,7-dienedioylcarnitine is an acylcarnitine. More specifically, it is an nona-5,7-dienedioic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. nona-5,7-dienedioylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine nona-5,7-dienedioylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

1H-Purine-2,6-dione, 3,7-dihydro-1,3-dimethyl-7-(3-(methylphenylamino)propyl)-

1,3-dimethyl-7-{3-[methyl(phenyl)amino]propyl}-2,3,6,7-tetrahydro-1H-purine-2,6-dione

C17H21N5O2 (327.1695)


   

1-Butyl-3-(1-naphthoyl)indole

(1-Butyl-1H-indole-3-yl)-1-naphthalenyl methanone

C23H21NO (327.1623)


D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D063385 - Cannabinoid Receptor Modulators D018377 - Neurotransmitter Agents > D063385 - Cannabinoid Receptor Modulators > D063386 - Cannabinoid Receptor Agonists

   

Flestolol

3-{[1-(carbamoylamino)-2-methylpropan-2-yl]amino}-2-hydroxypropyl 2-fluorobenzoate

C15H22FN3O4 (327.1594)


C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists

   

Cropodine

1beta,2-Dihydromonocrotaline

C16H25NO6 (327.1682)


   

10,11-Dihydro-8-(1-methylethyl)-11-(2-methylpropylidene)-6H-oxepino[2,3-d]pyrazino[1,2-a]pyrimidine-6,9(8H)-dione

10,11-Dihydro-8-(1-methylethyl)-11-(2-methylpropylidene)-6H-oxepino[2,3-d]pyrazino[1,2-a]pyrimidine-6,9(8H)-dione

C18H21N3O3 (327.1583)


   

JWH-015

(2-methyl-1-propyl-1H-indol-3-yl)-1-naphthalenyl-methanone

C23H21NO (327.1623)


D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D063385 - Cannabinoid Receptor Modulators D018377 - Neurotransmitter Agents > D063385 - Cannabinoid Receptor Modulators > D063386 - Cannabinoid Receptor Agonists

   

JWH-073

(1-butyl-1H-indol-3-yl)-1-naphthalenyl-methanone

C23H21NO (327.1623)


D006730 - Hormones, Hormone Substitutes, and Hormone Antagonists > D006728 - Hormones > D063385 - Cannabinoid Receptor Modulators D018377 - Neurotransmitter Agents > D063385 - Cannabinoid Receptor Modulators > D063386 - Cannabinoid Receptor Agonists CONFIDENCE standard compound; INTERNAL_ID 1704

   

(-)-4-<2-(dimethylamino)ethyl>phenyl beta-D-glucopyranoside|(-)-4-[2-(dimethylamino)ethyl]phenyl beta-D-glucopyranoside|hordenine-4-O-beta-D-glucoside

(-)-4-<2-(dimethylamino)ethyl>phenyl beta-D-glucopyranoside|(-)-4-[2-(dimethylamino)ethyl]phenyl beta-D-glucopyranoside|hordenine-4-O-beta-D-glucoside

C16H25NO6 (327.1682)


   

DTXSID101017295

DTXSID101017295

C23H21NO (327.1623)


   
   
   

JWH 073 2-naphthyl-N-(1,1-dimethylethyl) isomer

JWH 073 2-naphthyl-N-(1,1-dimethylethyl) isomer

C23H21NO (327.1623)


   
   
   
   

DTXSID901017368

DTXSID901017368

C23H21NO (327.1623)


   

(1-(sec-butyl)-1H-indol-3-yl)(naphthalen-2-yl)-methanone

(1-(sec-butyl)-1H-indol-3-yl)(naphthalen-2-yl)-methanone

C23H21NO (327.1623)


   

DTXSID601017369

DTXSID601017369

C23H21NO (327.1623)


   
   

Sinapine hydroxide

Sinapine (hydroxide)

C16H25NO6 (327.1682)


   

C18H21N3O3_6H-Oxepino[2,3-d]pyrazino[1,2-a]pyrimidine-6,9(8H)-dione, 10,11-dihydro-8-(1-methylethyl)-11-(2-methylpropylidene)-, (11Z)

NCGC00384906-01_C18H21N3O3_6H-Oxepino[2,3-d]pyrazino[1,2-a]pyrimidine-6,9(8H)-dione, 10,11-dihydro-8-(1-methylethyl)-11-(2-methylpropylidene)-, (11Z)-

C18H21N3O3 (327.1583)


   

C18H21N3O3_2H-Pyrazino[2,1-b]quinazoline-3,6(1H,4H)-dione, 10-hydroxy-4-(1-methylethyl)-1-(2-methylpropylidene)-, (1Z,4S)

NCGC00380832-01_C18H21N3O3_2H-Pyrazino[2,1-b]quinazoline-3,6(1H,4H)-dione, 10-hydroxy-4-(1-methylethyl)-1-(2-methylpropylidene)-, (1Z,4S)-

C18H21N3O3 (327.1583)


   

N1-(2-Methoxy-4-methylbenzyl)-N2-(2-(pyridin-2-YL)ethyl)oxalamide

N-[(2-methoxy-4-methylphenyl)methyl]-N-[2-(pyridin-2-yl)ethyl]ethanediamide

C18H21N3O3 (327.1583)


   

Cinereain

(4E)-4-(2-methylpropylidene)-7-(propan-2-yl)-15-oxa-2,5,8-triazatricyclo[8.5.0.0^{3,8}]pentadeca-1(10),2,11,13-tetraene-6,9-dione

C18H21N3O3 (327.1583)


   

JWH 018 2-naphthyl isomer

JWH 018 2-naphthyl isomer

C23H21NO (327.1623)


   

JWH 073 N-(2-methylpropyl) isomer

JWH 073 N-(2-methylpropyl) isomer

C23H21NO (327.1623)


   

JWH 073 N-(1-methylpropyl) isomer

JWH 073 N-(1-methylpropyl) isomer

C23H21NO (327.1623)


   

JWH 073 N-(1,1-dimethylethyl) isomer

JWH 073 N-(1,1-dimethylethyl) isomer

C23H21NO (327.1623)


   

JWH 073 2-naphthyl isomer

JWH 073 2-naphthyl isomer

C23H21NO (327.1623)


   

JWH 073 2-naphthyl-N-(2-methylpropyl) isomer

JWH 073 2-naphthyl-N-(2-methylpropyl) isomer

C23H21NO (327.1623)


   

JWH 073 2-naphthyl-N-(1-methylpropyl) isomer

JWH 073 2-naphthyl-N-(1-methylpropyl) isomer

C23H21NO (327.1623)


   

eucatropine hydrochloride

eucatropine hydrochloride

C17H26ClNO3 (327.1601)


   

1-{3-[4-(3-TRIFLUOROMETHYL-PHENYL)-PIPERAZIN-1-YL]-AZETIDIN-1-YL}-ETHANONE

1-{3-[4-(3-TRIFLUOROMETHYL-PHENYL)-PIPERAZIN-1-YL]-AZETIDIN-1-YL}-ETHANONE

C16H20F3N3O (327.1558)


   

Levobunolol hydrochloride

Levobunolol hydrochloride

C17H26ClNO3 (327.1601)


C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C72900 - Adrenergic Antagonist D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013565 - Sympatholytics D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D018674 - Adrenergic Antagonists C78283 - Agent Affecting Organs of Special Senses > C29705 - Anti-glaucoma Agent Levobunolol (l-Bunolol) hydrochloride is a potent and nonselective β-adrenergic receptor antagonist. Levobunolol hydrochloride is an ocular hypotensive agent and lowers mean intraocular pressure (IOP). Levobunolol hydrochloride can be used for glaucoma and superior oblique myokymia (SOM) research[1][2][3].

   

1H-INDAZOLE, 6-FLUORO-1-(2-FLUOROPHENYL)-3-(1-METHYL-4-PIPERIDINYL)-

1H-INDAZOLE, 6-FLUORO-1-(2-FLUOROPHENYL)-3-(1-METHYL-4-PIPERIDINYL)-

C19H19F2N3 (327.1547)


   

1-Dodecylpyridinium bromide

1-Dodecylpyridinium bromide

C17H30BrN (327.1561)


   

4-(Furfurylaminocarbonyl)benzeneboronic acid pinacol ester

4-(Furfurylaminocarbonyl)benzeneboronic acid pinacol ester

C18H22BNO4 (327.1642)


   

N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valine methyl ester

N-((N-Methyl-N-((2-isopropyl-4-thiazolyl)methyl)amino)carbonyl)-L-valine methyl ester

C15H25N3O3S (327.1617)


   

tilidine hydrochloride hemihydrate

tilidine hydrochloride hemihydrate

C17H26ClNO3 (327.1601)


   

4-Aminobenzo-18-crown-6

4-Aminobenzo-18-crown-6

C16H25NO6 (327.1682)


   

2-Cyano-3-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxa-borolan-2-yl)-phenyl]-acrylic acid ethyl ester

2-Cyano-3-[4-(4,4,5,5-tetramethyl-[1,3,2]dioxa-borolan-2-yl)-phenyl]-acrylic acid ethyl ester

C18H22BNO4 (327.1642)


   

(2E)-2-(HYDROXYIMINO)-N-(2-METHOXY-4-NITROPHENYL)ACETAMIDE

(2E)-2-(HYDROXYIMINO)-N-(2-METHOXY-4-NITROPHENYL)ACETAMIDE

C23H21NO (327.1623)


   

H-Gly-Pro-4MβNA

H-Gly-Pro-4MβNA

C18H21N3O3 (327.1583)


   

Cyclopentolate Hydrochloride

Cyclopentolate Hydrochloride

C17H26ClNO3 (327.1601)


C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D010276 - Parasympatholytics D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D009184 - Mydriatics C78283 - Agent Affecting Organs of Special Senses > C29706 - Mydriatic Agent Cyclopentolate (DL-Cyclopentolate) hydrochloride is an Atropine-like muscarinic receptors antagonist with a pKB value of 7.8 (on the circular ciliary muscle). Cyclopentolate hydrochloride is an anti-muscarinic agent commonly used in the ophthalmologic practice[1][2].

   

2-(TERT-BUTYL)-7-PIPERAZINO-5-(TRIFLUOROMETHYL)PYRAZOLO[1,5-A]PYRIMIDINE

2-(TERT-BUTYL)-7-PIPERAZINO-5-(TRIFLUOROMETHYL)PYRAZOLO[1,5-A]PYRIMIDINE

C15H20F3N5 (327.1671)


   

1,3,3-trimethylspiro[benzo[f]chromene-3,2-indole]

1,3,3-trimethylspiro[benzo[f]chromene-3,2-indole]

C23H21NO (327.1623)


   

3-(Furfurylaminocarbonyl)benzeneboronic acid pinacol ester

3-(Furfurylaminocarbonyl)benzeneboronic acid pinacol ester

C18H22BNO4 (327.1642)


   

2,6-Dimethyl-1-(3-[3-methyl-5-isoxazolyl]-propanyl)-4-[4-methyl-2H-tetrazol-2-YL]-phenol

2,6-Dimethyl-1-(3-[3-methyl-5-isoxazolyl]-propanyl)-4-[4-methyl-2H-tetrazol-2-YL]-phenol

C17H21N5O2 (327.1695)


   

Thiphenamil

Thiphenamil

C20H25NOS (327.1657)


C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent

   

3-Methyl-7-(2-phenylethyl)-8-(propylamino)purine-2,6-dione

3-Methyl-7-(2-phenylethyl)-8-(propylamino)purine-2,6-dione

C17H21N5O2 (327.1695)


   

5-Methyl-3-[2-(1-piperidinyl)ethylthio]-[1,2,4]triazino[5,6-b]indole

5-Methyl-3-[2-(1-piperidinyl)ethylthio]-[1,2,4]triazino[5,6-b]indole

C17H21N5S (327.1518)


   

2,6-Dimethyl-1-(3-[3-methyl-5-isoxazolyl]-propanyl)-4-[2n-methyl-2h-tetrazol-5-yl]-phenol

2,6-Dimethyl-1-(3-[3-methyl-5-isoxazolyl]-propanyl)-4-[2n-methyl-2h-tetrazol-5-yl]-phenol

C17H21N5O2 (327.1695)


   

3,4-dimethylideneheptanedioylcarnitine

3,4-dimethylideneheptanedioylcarnitine

C16H25NO6 (327.1682)


   

Nona-4,7-dienedioylcarnitine

Nona-4,7-dienedioylcarnitine

C16H25NO6 (327.1682)


   

Nona-3,7-dienedioylcarnitine

Nona-3,7-dienedioylcarnitine

C16H25NO6 (327.1682)


   

Nona-4,6-dienedioylcarnitine

Nona-4,6-dienedioylcarnitine

C16H25NO6 (327.1682)


   

Nona-3,6-dienedioylcarnitine

Nona-3,6-dienedioylcarnitine

C16H25NO6 (327.1682)


   

Nona-5,7-dienedioylcarnitine

Nona-5,7-dienedioylcarnitine

C16H25NO6 (327.1682)


   

(2E,7E)-Nona-2,7-dienedioylcarnitine

(2E,7E)-Nona-2,7-dienedioylcarnitine

C16H25NO6 (327.1682)


   
   

N-[4-(4-propanoylpiperazin-1-yl)phenyl]furan-2-carboxamide

N-[4-(4-propanoylpiperazin-1-yl)phenyl]furan-2-carboxamide

C18H21N3O3 (327.1583)


   

5-(Azepan-1-yl)-2-(3,4-dimethoxyphenyl)-1,3-oxazole-4-carbonitrile

5-(Azepan-1-yl)-2-(3,4-dimethoxyphenyl)-1,3-oxazole-4-carbonitrile

C18H21N3O3 (327.1583)


   

[4-(2-Ethoxyphenyl)-1-piperazinyl]-(1-oxido-4-pyridin-1-iumyl)methanone

[4-(2-Ethoxyphenyl)-1-piperazinyl]-(1-oxido-4-pyridin-1-iumyl)methanone

C18H21N3O3 (327.1583)


   

Thr-Ala-His

Thr-Ala-His

C13H21N5O5 (327.1543)


A tripeptide composed of L-threonine, L-alanine, and L-histidine joined by peptide linkages.

   

N-(2,4-dimethylphenyl)-4-{2-[(5-methyl-2-furyl)methylene]hydrazino}-4-oxobutanamide

N-(2,4-dimethylphenyl)-4-{2-[(5-methyl-2-furyl)methylene]hydrazino}-4-oxobutanamide

C18H21N3O3 (327.1583)


   
   
   
   
   
   

(S)-cyclopentolate hydrochloride

(S)-cyclopentolate hydrochloride

C17H26ClNO3 (327.1601)


   

(R)-cyclopentolate hydrochloride

(R)-cyclopentolate hydrochloride

C17H26ClNO3 (327.1601)


   

(11Z)-10,11-Dihydro-8-(1-methylethyl)-11-(2-methylpropylidene)-6H-oxepino[2,3-d]pyrazino[1,2-a]pyrimidine-6,9(8H)-dione

(11Z)-10,11-Dihydro-8-(1-methylethyl)-11-(2-methylpropylidene)-6H-oxepino[2,3-d]pyrazino[1,2-a]pyrimidine-6,9(8H)-dione

C18H21N3O3 (327.1583)


   

(1r,4s,5r,6s,10r,16r)-5,6-dihydroxy-4,5,6-trimethyl-2,8-dioxa-13-azatricyclo[8.5.1.0¹³,¹⁶]hexadecane-3,7-dione

(1r,4s,5r,6s,10r,16r)-5,6-dihydroxy-4,5,6-trimethyl-2,8-dioxa-13-azatricyclo[8.5.1.0¹³,¹⁶]hexadecane-3,7-dione

C16H25NO6 (327.1682)


   

(1r,7s)-7-{[(2,3-dihydroxypropanoyl)oxy]methyl}-hexahydro-1h-pyrrolizin-1-yl (2e)-2-methylbut-2-enoate

(1r,7s)-7-{[(2,3-dihydroxypropanoyl)oxy]methyl}-hexahydro-1h-pyrrolizin-1-yl (2e)-2-methylbut-2-enoate

C16H25NO6 (327.1682)


   

7-chloro-3-(4-cyclopropyl-2-methylbuta-1,3-dien-1-yl)-1-methyl-hexahydro-2h-indolizine-1,2,8-triol

7-chloro-3-(4-cyclopropyl-2-methylbuta-1,3-dien-1-yl)-1-methyl-hexahydro-2h-indolizine-1,2,8-triol

C17H26ClNO3 (327.1601)


   

(4e)-6-hydroxy-7-isopropyl-4-(2-methylpropylidene)-15-oxa-2,5,8-triazatricyclo[8.5.0.0³,⁸]pentadeca-1(10),2,5,11,13-pentaen-9-one

(4e)-6-hydroxy-7-isopropyl-4-(2-methylpropylidene)-15-oxa-2,5,8-triazatricyclo[8.5.0.0³,⁸]pentadeca-1(10),2,5,11,13-pentaen-9-one

C18H21N3O3 (327.1583)


   

5,6-dihydroxy-4,5,6-trimethyl-2,8-dioxa-13-azatricyclo[8.5.1.0¹³,¹⁶]hexadecane-3,7-dione

5,6-dihydroxy-4,5,6-trimethyl-2,8-dioxa-13-azatricyclo[8.5.1.0¹³,¹⁶]hexadecane-3,7-dione

C16H25NO6 (327.1682)


   

(2s,3r,4s,5s,6r)-2-{4-[2-(dimethylamino)ethyl]phenoxy}-6-(hydroxymethyl)oxane-3,4,5-triol

(2s,3r,4s,5s,6r)-2-{4-[2-(dimethylamino)ethyl]phenoxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C16H25NO6 (327.1682)


   

(1r,7s)-7-{[(2,3-dihydroxypropanoyl)oxy]methyl}-hexahydro-1h-pyrrolizin-1-yl (2z)-2-methylbut-2-enoate

(1r,7s)-7-{[(2,3-dihydroxypropanoyl)oxy]methyl}-hexahydro-1h-pyrrolizin-1-yl (2z)-2-methylbut-2-enoate

C16H25NO6 (327.1682)


   

[(2-amino-5-carbamimidamido-1-hydroxypentylidene)amino](1-hydroxy-2-oxocyclopent-3-en-1-yl)acetic acid

[(2-amino-5-carbamimidamido-1-hydroxypentylidene)amino](1-hydroxy-2-oxocyclopent-3-en-1-yl)acetic acid

C13H21N5O5 (327.1543)


   

(1s,2s,3s,7s,8s,8ar)-7-chloro-3-[(1e,3e)-4-cyclopropyl-2-methylbuta-1,3-dien-1-yl]-1-methyl-hexahydro-2h-indolizine-1,2,8-triol

(1s,2s,3s,7s,8s,8ar)-7-chloro-3-[(1e,3e)-4-cyclopropyl-2-methylbuta-1,3-dien-1-yl]-1-methyl-hexahydro-2h-indolizine-1,2,8-triol

C17H26ClNO3 (327.1601)


   

2-{4-[2-(dimethylamino)ethyl]phenoxy}-6-(hydroxymethyl)oxane-3,4,5-triol

2-{4-[2-(dimethylamino)ethyl]phenoxy}-6-(hydroxymethyl)oxane-3,4,5-triol

C16H25NO6 (327.1682)